Understanding CDK 4/6 Inhibition

Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Earn CME points and track your learning activity with hundreds of hours of continuing medical education.

Understanding CDK 4/6 Inhibition

This module is designed to support the professional development of healthcare professionals interested in the science behind CDK 4/6 inhibition.

This course is a collection of modules on breast cancer CDK 4/6 inhibition, developed to support the professional development of three distinct healthcare professions.The content is based on the presentations that were given during the Coming of Age for CDK 4/6 Inhibitors industry satellite symposium held at the ESMO 2016 conference in Copenhagen, Denmark. The objective of this satellite symposium was to establish and deliver a globally leading educational initiative that has a significant impact on clinical practice.

Published August 2017.

Module

English

0 CME Points

Save View course

Complete Complete

Target audience

This module is for medical practitioners who wish to learn the developments in CDK 4/6 inhibitors for breast cancer patients.

Learning objectives

By the end of this module, you should be able to:

Focus on CDK4 and 6 as key regulators of the G1- S transition of the cell cycle.
Acknowledge that an array of substrates for CDK4 and 6 have been identified, including the retinoblastoma protein, RB1, which can potentially lead to drug target discovery.

IT Requirements

This module requires the learner to have a good, stable internet connection and runs best on INTERNET EXPLORER 7 AND ABOVE, and MOZILLA FIREFOX on either Windows or MacOS. FLASH ADD ON is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.
If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Disclosure policy

ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Pfizer.

Support

Production of this module was funded by an unrestricted grant from Pfizer.

Understanding CDK 4/6 Inhibition

Target audience

Learning objectives

IT Requirements

Disclosure policy

Support

More from ecancer